Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately high-dose co...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet respiratory medicine Vol. 9; no. 1; p. 57
Main Authors:	Heaney, Liam G, Busby, John, Hanratty, Catherine E, Djukanovic, Ratko, Woodcock, Ashley, Walker, Samantha M, Hardman, Timothy C, Arron, Joseph R, Choy, David F, Bradding, Peter, Brightling, Christopher E, Chaudhuri, Rekha, Cowan, Douglas C, Mansur, Adel H, Fowler, Stephen J, Niven, Robert M, Howarth, Peter H, Lordan, James L, Menzies-Gow, Andrew, Harrison, Tim W, Robinson, Douglas S, Holweg, Cecile T J, Matthews, John G, Pavord, Ian D
Format:	Journal Article
Language:	English
Published:	England 01.01.2021
Subjects:	Acute Disease Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - adverse effects Adrenal Cortex Hormones - therapeutic use Algorithms Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Asthma - drug therapy Biomarkers - blood Cell Adhesion Molecules - blood Drug Dosage Calculations Eosinophils Female Humans Leukocyte Count Male Middle Aged Nitric Oxide - metabolism Risk Factors Single-Blind Method
ISSN:	2213-2619, 2213-2619
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!